{"id":"https://openalex.org/W1925323738","doi":"https://doi.org/10.1111/dom.12263","title":"Changes in weight loss\u2010related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin","display_name":"Changes in weight loss\u2010related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin","alternate_titles":[],"publication_year":2014,"publication_date":"2014-02-09","ids":{"openalex":"https://openalex.org/W1925323738","doi":"https://doi.org/10.1111/dom.12263","mag":"1925323738","pmid":"https://pubmed.ncbi.nlm.nih.gov/24443876"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12263","doi":"https://doi.org/10.1111/dom.12263","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12263","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1925323738"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035420893","display_name":"Susan Grandy","orcid":"https://orcid.org/0000-0002-8030-5845","observed_orcids":["https://orcid.org/0000-0002-8030-5845"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"S. Grandy","raw_affiliation_strings":["AstraZeneca LP Wilmington DE USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca LP Wilmington DE USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Hashemi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Hashemi","raw_affiliation_strings":["AstraZeneca Molndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Molndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110567169","display_name":"AM Langkilde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A.\u2010M. Langkilde","raw_affiliation_strings":["AstraZeneca Molndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Molndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009695940","display_name":"Shamik J. Parikh","orcid":"https://orcid.org/0009-0001-2380-439X","observed_orcids":["https://orcid.org/0009-0001-2380-439X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Parikh","raw_affiliation_strings":["AstraZeneca LP Wilmington DE USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca LP Wilmington DE USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041913215","display_name":"C. David Sj\u00f6str\u00f6m","orcid":"https://orcid.org/0000-0002-8380-9766","observed_orcids":["https://orcid.org/0000-0002-8380-9766"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. D. Sj\u00f6str\u00f6m","raw_affiliation_strings":["AstraZeneca Molndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Molndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5035420893"],"corresponding_institution_ids":["https://openalex.org/I4210150756"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.9433,"has_fulltext":false,"cited_by_count":46,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.93950552,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"16","issue":"7","first_page":"645","last_page":"650"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9829999804496765},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7739999890327454},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9810000061988831},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9779999852180481},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.8849999904632568},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.621999979019165},{"id":"https://openalex.org/keywords/self-esteem","display_name":"self-esteem","score":0.6880000233650208},{"id":"https://openalex.org/keywords/physical-health","display_name":"physical health","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.9912946820259094},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.6499139070510864},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5977514386177063},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.5647162795066833},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5080838203430176},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.46765393018722534},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.46230828762054443},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4524742662906647},{"id":"https://openalex.org/C74909509","wikidata":"https://www.wikidata.org/wiki/Q10387","display_name":"Gerontology","level":1,"score":0.3420279324054718},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.32334381341934204},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.17804434895515442},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006304","descriptor_name":"Health Status","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.12263","doi":"https://doi.org/10.1111/dom.12263","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12263","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:24443876","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24443876","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1973240292","https://openalex.org/W1981928922","https://openalex.org/W2008443217","https://openalex.org/W2017312421","https://openalex.org/W2018472985","https://openalex.org/W2056523905","https://openalex.org/W2080253540","https://openalex.org/W2080383778","https://openalex.org/W2096559770","https://openalex.org/W2122077393","https://openalex.org/W2123850120","https://openalex.org/W2147325147","https://openalex.org/W2167245776","https://openalex.org/W2172193326","https://openalex.org/W2789732774"],"related_works":["https://openalex.org/W2317567593","https://openalex.org/W2465295773","https://openalex.org/W2167245776","https://openalex.org/W2003728844","https://openalex.org/W1994396689","https://openalex.org/W2329424314","https://openalex.org/W7153303629","https://openalex.org/W3093126458","https://openalex.org/W2795155615","https://openalex.org/W2641200828"],"abstract_inverted_index":{"AIMS:":[0],"This":[1,164],"study":[2,72],"evaluated":[3],"change":[4,15],"in":[5,66,115,139,181,227,248,259],"health-related":[6],"quality":[7],"of":[8,81,100,117,171,210,217],"life":[9],"(HRQOL)":[10],"associated":[11,46,179,245,256],"with":[12,18,25,47,53,73,120,143,246,257,264],"ongoing":[13,175,206,252],"weight":[14,49,110,153,176,207,220,223,242,253,265],"among":[16,202],"patients":[17,118,149,157,173,203,218],"type":[19],"2":[20,32],"diabetes":[21],"mellitus":[22],"(T2DM)":[23],"treated":[24,119],"dapagliflozin,":[26],"a":[27,67,74,109,167,199,213],"highly":[28],"selective":[29],"sodium-glucose":[30],"cotransporter":[31],"(SGLT2)":[33],"inhibitor":[34],"that":[35],"lowers":[36],"blood":[37],"glucose":[38,42],"by":[39],"increasing":[40],"urinary":[41],"excretion":[43],"and":[44,98,178,193,231,238],"is":[45],"body":[48,86],"reductions.":[50],"METHODS:":[51],"Patients":[52,88],"T2DM":[54],"who":[55,136,204],"had":[56,150],"inadequate":[57],"glycaemic":[58],"control":[59],"on":[60,85],"metformin":[61],"(MET)":[62],"alone":[63],"were":[64],"enrolled":[65],"24-week,":[68],"double-blind,":[69],"randomized,":[70],"placebo-controlled":[71],"78-week":[75],"extension":[76],"to":[77,93,104,166],"evaluate":[78],"the":[79,91],"effect":[80],"dapagliflozin":[82,121],"+":[83,124,131],"MET":[84,125,132],"weight.":[87],"also":[89],"completed":[90],"Study":[92],"Help":[94],"Improve":[95],"Early":[96],"evaluation":[97,188],"management":[99],"risk":[101],"factors":[102],"Leading":[103],"Diabetes":[105],"Weight":[106],"Questionnaire-9":[107],"(SHIELD-WQ-9),":[108],"change-related":[111],"HRQOL":[112,140,183,233,261],"survey.":[113],"Difference":[114],"proportions":[116],"10":[122],"mg":[123],"(n":[126,133],"=":[127,134],"89)":[128],"or":[129],"placebo":[130,156],"91)":[135],"reported":[137,205,225],"improvement":[138,247],"was":[141,244,255],"analysed":[142],"Fisher's":[144],"exact":[145],"test.":[146],"RESULTS:":[147],"Dapagliflozin":[148],"significantly":[151,214],"greater":[152,169,215],"loss":[154,177,208,221,243,254],"than":[155,195],"over":[158],"102":[159],"weeks":[160,235],"(p":[161],"<":[162],"0.05).":[163],"corresponded":[165],"numerically":[168],"proportion":[170,216],"dapagliflozin-treated":[172],"reporting":[174,219],"improvements":[180,226,258],"most":[182],"domains":[184,262],"at":[185,234],"three":[186],"different":[187],"points":[189],"(weeks":[190],"24,":[191,236],"50":[192,237],"102)":[194],"placebo-treated":[196],"patients.":[197],"In":[198],"post-hoc":[200],"analysis":[201],"regardless":[209],"treatment":[211],"arm,":[212],"versus":[222],"gain":[224],"physical":[228],"health,":[229],"self-esteem":[230],"overall":[232,249],"102.":[239],"CONCLUSIONS:":[240],"Dapagliflozin-induced":[241],"HRQOL.":[250],"Overall,":[251],"several":[260],"compared":[263],"gain.":[266]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1925323738","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
